MGI Pharma reports interim data

MOGN reported updated interim results from two ongoing Phase II trials of its irofulven acylfulvene compound ( MGI 114) in ovarian cancer patients. Interim results from 18 evaluable refractory ovarian cancer patients showed one patient achieved the primary end point of a partial response, one patient had a partial response in only the first of two measurements, and one patient had stable disease. Interim results from 27 ovarian cancer patients with recurrent or persistent disease showed one patient achieved complete clinical response, five patients achieved the primary end point of a partial response, and seven patients had stable disease. ...